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Abstract
Background: PALB2 1592delT mutation is associated with increased breast cancer and suggestive
prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants
associate to increased PRCA risk and clinically describe patients with formerly found PALB2
1592delT mutation.
Methods: Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285)
with complete clinical data were initially screened for variants in the coding region and splice sites
of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n =
463).
Results: From our clinically defined sample set we identified total of six variants in PALB2. No novel
variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers,
including the previously described family carrying PALB2 1592delT, revealed a trend towards
aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C
(MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency
among carriers with altered genotype.
Conclusions: Though any of the detected PALB2 variants do not associate to PRCA in population
level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility
at individual level.
Introduction
Prostate cancer (PRCA) is the most frequently diagnosed
cancer among men in the Western world [1]. The inci-
dence of PRCA has been increasing throughout the last
decade, partly due to the earlier diagnosis provided by the
prostate specific antigen (PSA) test, introduced in the
1990s. In Finland, the highest incidence of 115/100 000
was observed in 2005. In 2007 there were 4188 newly-
diagnosed PRCA cases with the age-adjusted incidence
rate of 85.9/100,000 [2]. Similar high increase and now
decline have been observed in most Western industrial-
ized countries [3].
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behind PRCA susceptibility [4]. Early linkage studies and
more recent genome-wide association analyses have
revealed multiple susceptibility loci for PRCA [5-7]. How-
ever, both causal variants and genes of the associated loci
in are still not known and the identified PRCA risk vari-
ants only account for a fraction of the overall genetic var-
iance for PRCA risk [8-10].
DNA repair pathway genes have an undisputed role in
cancer progression and inherited mutations in them have
been strongly associated with different cancers. BRCA1
and BRCA2 are both tumor suppressor genes involved in
DNA repair and mutations in these genes predominantly
predispose carriers to breast and ovarian cancers [11].
Potential links to PRCA have been studied for both of
these genes and mutations in BRCA2 lead to an increased
risk for the disease in multiple studies [12,13]. In an Ice-
landic study, mutations in BRCA2 (999del5, Icelandic
founder mutation) are associated with a poorly differenti-
ated, advanced type of PRCA [14]. These results are also
consistent with results from a recent study in the UK,
where a significantly higher Gleason score was observed
among BRCA2 mutation carriers than with non-carriers.
These findings suggest that BRCA2 is a high-risk PRCA sus-
ceptibility gene and mutational analysis could be used as
a prognostic marker for aggressive PRCA [15]. However,
Finnish BRCA1/2 founder mutations do not associate
with PRCA predisposition among Finnish PRCA patients
[16]. This does not exclude the possibility of these genes
to be involved in PRCA susceptibility but no studies have
been published where the whole genes would have been
sequenced in large data sets. Nevertheless an increased
risk for PRCA in Finnish breast cancer families carrying
BRCA2 mutations has been observed [17]. Moreover,
mutations of CHEK2, a gene acting in the same DNA
repair route as BRCA1/2, have been shown to have a sig-
nificant role in PRCA susceptibility in Finland [18].
PALB2 is a BRCA2 binding protein and the BRCA2-PALB2
interaction is essential for BRCA2-mediated DNA repair
[19]. Recently it was shown that proper PALB2 function is
necessary for the homologous recombination repair via
interaction with BRCA1, revealing that PALB2 is actually a
linker between BRCA1 and BRCA2 [20]. In the Finnish
study by Erkko and colleagues a novel PALB2 founder
mutation (c.1592delT) was identified among Finnish
breast cancer families (OR 11.3, CI 1.8-57.8) increasing
the risk to breast cancer 4-fold [21]. In the same study the
c.1592delT mutation was observed also from a patient
with familial PRCA (1/164) but none of 475 unselected
cases were carriers of the mutation. No statistically signif-
icant association with PRCA and c.1592delT was detected
and no other variants were screened for in PRCA patients.
Here, to investigate the role of possible other PALB2 vari-
ants, we screened all PALB2 exons(exons 1-13) in a cohort
of 938 Finnish PRCA patients including both familial and
unselected cases.
Material and methods
Patients and controls
A population-based cohort was collected from 1999 to
2005 from patients diagnosed with PRCA in the Pirkan-
maa Hospital District that serves a population of a half a
million inhabitants. The mean age at diagnosis for the
760 unselected patients was 62 (range 43-77), The
median primary PSA and Gleason score were 8.9 and 6.4,
respectively. The controls (n = 760) consisted of DNA
samples from anonymous male blood donors obtained
from the Finnish Red Cross.
A detailed description of the collection of the PRCA fami-
lies has been previously described elsewhere [22]. In this
study, we analysed 178 families (youngest affected male
from each family) with two or more affected first-degree
relatives. The average number of affected family members
was three. Familial cancer data was attained from the
Finnish Cancer Registry and detailed clinical information,
including Gleason score, WHO grade, PSA at the time of
diagnosis, TNM stage and primary treatment from hospi-
tal records.
To examine the association between the variants and the
disease aggressiveness a subgroup of 380 with clinically
aggressive disease was analyzed. Consequently clinically
aggressive disease patients were selected according to
Gleason score over seven and an age at diagnosis less than
61 years.
Mutation analysis of PALB2
All familial samples had been previously screened for the
11 Finnish BRCA1 and seven BRCA2 founder mutations
[16]. DNA samples from each family (n = 178), 285 unse-
lected cases and 470 control samples were initially used
for direct sequencing of the entire coding region and
splice sites of PALB2. Unselected cases for screening the
whole gene were early onset cases with Gleason score over
seven. Additional analyses were carried out on four vari-
ants that showed a trend for association (PALB2
c.1592delT, 1674A>G, 2993G>A and 3300T>G). Unse-
lected cases for additional analysis included 95 early
onsets, aggressive cases and 368 non-aggressive cases with
average age at diagnosis 67 years (range 63-77). Control
samples in both primary and additional analysis were
anonymous male blood donors from the Finnish Red
Cross.
Mutation detection was performed through resequencing
using the ABI PRISM BigDye Terminator Cycle Sequenc-
ing Ready Reaction kit with the ABI 3130xl sequencerPage 2 of 6
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sequence variants were produced to correspond to the
GenBank reference sequences for PALB2 (NM_024675.3).
Primer sequences are available on request. Variants were
identified using Sequencher software 4.7 (Gene Codes
Corporation, Ann Arbor, Mi). Loss of heterozygosity
(LOH) analysis was carried out on two available tumor
samples from the family with the segregating PALB2
1592delT. Selected sections of formalin fixed paraffin
embedded tumors were obtained according to pathologist
declaration. After tumor deparaffinization, DNA was
extracted using a standard proteinase K protocol.
Sequence from the tumor samples was compared to the
patients' DNA sample from their peripheral blood.
DNA damage response in PALB2 deficient cell line
Peripheral blood leucocytes from two cancerous individu-
als carrying PALB2 1592delT mutation were immortalized
with Epstein-Barr virus (EBV) and sensitized to DNA
crosslinking agent mitomycin C (MMC). Cells were
treated with 0 nM, 1 nM, 5 nM, 10 nM and 50 nM MMC
for 96 h and their viability was assayed by CellTiter-Blue®
Cell Viability Assay (Promega Corporation, Madison, WI,
USA).
Statistical analyses
To validate significance of variants, the odds ratios and
95% confidence intervals were calculated and association
analyses were made using the Fisher's exact test. Analyses
were done using SPSS 12.0 statistical software. Pairwise
linkage disequilibrium between three most frequently
detected variants (1674A>G, 2993G>A and 3300T>G) in
PALB2 were analysed with Haploview 4.1. To define the
haplotypes of cases familial and unselected cases were
combined.
Results and Discussion
Mutation analysis
Prompted by the previous observation that the Finnish
truncating founder mutation, PALB2 c.1592delT, was
identified segregating in one family with four PRCA cases
[21], we wanted to study the contribution of other possi-
ble PALB2 mutations. Probands from 178 Finnish HPC
(hereditary prostate cancer) families and 285 unselected
cases were screened for the entire coding region of PALB2.
Total of six variants were detected in the coding regions
and the exon-intron boundaries of PALB2 (Table 1). All
the variants have been previously described and only the
truncating mutation (c.1592delT) has been shown to
have functional consequences on DNA damage response.
Association of four detected variants (c.1592delT,
1674A>G, 2993G>A and 3300T>G) were assessed in
more detail in a larger set of unselected cases and controls.
The truncating c.1592delT mutation was detected in two
sporadic cases in addition to the previously described
family 310 and in one control sample [21]. Interestingly,
family 310 has now been found to have also stomach and
skin cancer, in addition to earlier described breast cancer,
as indicated in Figure 1 and Table 2. Three of the detected
variants, 1674A>G in exon 4, 2993G>A in exon 9 and
3300T>G in exon 12, co-existed in six patients out of 178
familial samples (OR 1.52 CI 95% 0.6-3.9), 20/748 unse-
lected cases (OR 1.20 CI 95% 0.6-2.3) and in 17/760 of
the controls. To assess question whether these three vari-
ants have a stronger joint effect that would strengthen the
trend seen with singletons a haplotype analysis was per-
formed. The strongest linkage was between 1674A>G and
2993G>A (D'= 0.975; r2 = 0.14, LOD 34.7) when 1886
case chromosomes and 1714 control chromosomes were
analysed. Although these two variants appeared to have a
frequency in PRCA cases that is higher than the Finnish
population control frequency, their combined haplotype
gave no improved results, i.e. none of the haplotype com-
binations showed significant association with the disease.
Variant 2993G>A is now reported for the first time in the
Finnish population since it did not come up in the study
of Finnish breast cancer patients [21]. As reported by Rah-
man and colleagues [23] the 2993G>A variant is possibly
Family 310 segregating the PALB mutationigure 
Family 310 segregating the PALB mutation. Minus-
symbol signifies a person that has been screened for the 
PALB2 1592delT mutation, but found negative. Clinical infor-
mation on this family is found in Table 2. Index person is 
marked with a black triangle, black square denotes persons 
with prostate cancer, grey circle indicates breast cancer 
cases and black square with white and grey corners signifies 
patient with prostate, stomach and skin cancers.Page 3 of 6
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intolerant from tolerant) analysis.
We found that the 2993G>A variant exhibits a borderline
significant odds ratios in a subgroup of 380 unselected
cases with a Gleason score over seven and an age at diag-
nosis less than 61 years (20/380; OR 1.9; 95% CI 1.0-3.5).
Edwards and colleagues [24] have presented similar age
related observation with BRCA2 mutations in prostate
cancer. They reported protein truncating mutations in
BRCA2 to associate with PRCA diagnosed at or before age
of 55. Our subgroup analysis also revealed that the variant
1674A>G has an OR of 1.4 (86/380; 95% CI 1.0-1.9) in a
group of 368 patients with an average age at diagnosis of
67 years. However, the 1674A>G variant is commonly
found in the Finnish population and well tolerated
according to SIFT analysis, indicating no clear contribu-
tion to cancer formation. Similarly, the Val932 Met
(2794G>A) change in exon 8 is well tolerated and has no
effect on protein function [23].
In order to obtain information about loss of heterozygos-
ity in the tumors from c.1592delT mutation positive
patients, two available paraffin-embedded tumors were
analysed. Repeated PCR-analysis did not reveal existence
of LOH, which argues against the role as tumor suppressor
gene. However the sample size is very small and therefore
more tumor samples from PALB2-associated tumors
needs to be characterized to be able to reliable assess
PALB2 function in tumor formation. To date there is only
one report indicating LOH in PALB2 related tumors.
Unfortunately also this study lacks a statistical power to
make an appropriate conclusion about the role of PALB2
in tumorigenesis [25].
DNA damage response in PALB2 deficient cell line
Previously, MMC sensitivity test to c.1592delT mutation
has been done in a reporter cell line [21]. To test whether
the previously described PALB2 c.1592delT mutation has
functional consequences also in a heterozygous form, as
present in all our patients, we predisposed two lymphob-
last cell lines with c.1592delT and a wild type carrying
control cell line to DNA cross linking agent MMC (Figure
2). c.1592delT mutation carriers were patients (15 and
24) from family 310 earlier described by Erkko et al. [21].
In both cell lines MMC-induced growth inhibition was
observed suggesting PALB2 haploinsufficiency. It is also
possible that dominant-negative effect is affecting in
tumor formation in these patients.
Geographical and ethnical differences in the PRCA sus-
ceptibility alleles have been previously reported in the
Table 1: Observed PALB2 variants among the Finnish familial and unselected prostate cancer cases.
Exon/Intron Nt change Amino acid Change Carrier Frequency (OR; 95% CI)
Familial Unselected Controls
PALB2
Ex 4 1592delT Leu531>Fs>Stop 1/178 (0.6%) (4.3; 0.3-68.8) 2/748 (0.3%) (2.0; 0.2-22.2) 1/760 (0.2%)
Ex 4 1674A>G Gln559Agr 36/178 (20.2%) (1.2; 0.8-1.8) 153/748(20.5%) (1.2; 0.9-1.5) 134/760(18.0%)
Ex 8 2794G>A Val932 Met 4/178 (2.2%) (1.0; 0.3-3.4) 7/285(2.5%) (1.2; 0.4-3.1) 10/470 (2.1%)
Ex 9 2993G>A Gly998Glu 8/178 (4.5%) (1.6; 0.7-3.5) 35/748 (4.9%) (1.6; 0.9-2.8) 22/760 (2.9%)
Ex 12 3300T>G Thr1100Thr 6/178 (3.4%) (0.8; 0.3-2.0) 30/748 (3.9%) (1.0: 0.6-1.7) 30/760 (3.9%)
5'UTR G>A - 8/178 (4.5%) (1.8; 0.7-4.4) 14/285 (4.9%) (2.0; 0.9-4.3) 12/470 (2.6%)
Table 2: Clinical characteristics of family 310. The patient number refers to the number in the pedigree in Figure 1.
Patient Cancer Histology Age at 
diagnosis
Reason for 
diagnosis
First 
treatment
Primary 
PSA value
WHO 
grading
Gleason 
grading
TNM 
grading
IHC
6 Prostate Adenocarcinoma 83 NA NA NA NA NA NA
11 Prostate Adenocarcinoma 68 Symptoms Orchiectomy NA III Na T3NXMX
13 Stomach Adenocarcinoma 70 Symptoms Gastrectomy NA NA Na T4N0 M0
13 Skin Carcinoma 
epidermoides
75 NA Resection NA NA Na NA
13 Prostate Adenocarcinoma 76 Elevated PSA Orchiectomy 47 III 2+3 = 5 T2NXMX
15 Prostate Adenocarcinoma 69 Elevated PSA Brakytherapy 7.7 I 2+3 = 5 T1cNXMX
17 Breast Ductal carcinoma 52 Screening 
mammography
Mammary 
resection
NA I Na T1N0 M0 ER+, PR+
24 Breast Ductal carcinoma 49 Mammography Mammary 
resection
NA I Na T1N0 M0 NA
IHC = immunohistochemistry, NA = not availablePage 4 of 6
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therefore, variation in the PALB2 mutation spectrum in
different populations would not be surprising. In the
present study and in the study by Erkko et al. [21], the
number of mutations found in PALB2 is relatively small
among both Finnish breast and PRCA patients, with nine
and six variants detected, respectively, compared to the
British breast cancer family study by Rahman and col-
leagues [23] where a total of 50 variants and five
frameshift mutations were reported. Recently, Tischkow-
itz and colleagues [26] reported a study of 95 US PRCA
patients from Michigan, all diagnosed at < 55 years of age.
Eleven variants in PALB2 were found, but none of them
were truncating and no association with the disease was
observed. When comparing our patients to those very
early-onset patients studied by Tischkowitz and col-
leagues [26] there is a clear difference in the mean age of
onset between the two datasets. On the other hand, no
variants were found in the 14 Ashkenazi-Jewish and 21
French-Canadian PRCA cases with family history of can-
cer [27]. In Finland, the smaller number of variation
found likely reflects the known genetic homogeneity and
founder effect of the population [28].
Our findings indicate that no other deleterious PALB2 var-
iants, except 1592delT mutation, contribute even margin-
ally to PRCA risk in Finland. However, it remains possible
that other genes from the BRCA1-PALB2-BRCA2 pathway
have PRCA-predisposing alleles
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